Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in <i>KRAS</i>- and <i>BRAF</i>-mutant cancer cells.
Ontology highlight
ABSTRACT: The Ras-mitogen-activated protein kinase (MAPK) pathway is a major target for cancer treatment. To better understand the genetic pathways that modulate cancer cell sensitivity to MAPK pathway inhibitors, we performed a CRISPR knockout screen with MAPK pathway inhibitors on a colorectal cancer (CRC) cell line carrying mutant KRAS. Genetic deletion of the catalytic subunit of protein phosphatase 6 (PP6), encoded by PPP6C, rendered KRAS- and BRAF-mutant CRC and BRAF-mutant melanoma cells more resistant to these inhibitors. In the absence of MAPK pathway inhibition, PPP6C deletion in CRC cells decreased cell proliferation in two-dimensional (2D) adherent cultures but accelerated the growth of tumor spheroids in 3D culture and tumor xenografts in vivo. PPP6
SUBMITTER: Zhang H
PROVIDER: S-EPMC11238902 | biostudies-literature | 2024 May
REPOSITORIES: biostudies-literature
ACCESS DATA